5

Abstract

The present invention provides a pharmaceutical composition for use as a Th2 differentiation inhibitor comprising a compound represented by Formula (I):

$$\begin{pmatrix} C \\ W^3 \end{pmatrix} - V^2 - \begin{pmatrix} B \\ W^2 \end{pmatrix} - V^1 - \begin{pmatrix} A \\ W^1 \end{pmatrix} - X - Y$$
 (I)

wherein each of ring A, ring B and ring C is an aromatic carbocyclic ring, a heterocyclic ring and the like, X is a single bond, -O-, -CH₂-, -NH-, -SO- and the like, Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl and the like, each of V1 and V2 is a single bond, -O-, -NH-, -OCH2- and the like,

a prodrug, pharmaceutically acceptable salt or solvate thereof. 10